Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.

Drug Category : Array
Conference Category : Array
Lead Author : Lunning M, et al.
Published Date : 20/06/2015
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/1303%20Lugano%202015%20FINAL.PDF
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top